


## CLAIMS

1. A method for treating severe heart failure, comprising administering to a patient in need thereof a therapeutically effective amount of a benzazepine compound  
 5 of the formula (1):



wherein R¹ is a hydrogen atom or a halogen atom, R² is a hydroxy group, or a group of the formula: -NR⁵R⁶ wherein R⁵ and R⁶ are the same or different and are each a hydrogen atom or a lower alkyl group, R³ is a hydrogen atom, a halogen atom, a lower alkyl group, or a lower alkoxy group, R⁴ is a halogen atom, a lower alkyl group or a lower alkoxy group, or a pharmaceutically acceptable salt thereof.

- 10 2. The method for treating severe heart failure according to claim 1, wherein the daily dose of the active compound is in the range of less than 0.6 mg/kg.

- 15 3. The method for treating severe heart failure according to claim 1, wherein the daily dose of the active compound is in the range from 0.1 mg/kg to less than 0.6

mg/kg.

4. The method for treating severe heart failure according to claim 1, wherein the dose of the active compound is in the range of 15 to 45 mg/body per day.


5 5. The method for treating severe heart failure according to claim 1, wherein the active compound is 5-dimethylamino-1-[4-(2-methylbenzoylamino)benzoyl]-2,3,4,5-tetrahydro-1H-benzazepine or a pharmaceutically acceptable salt thereof.

10 6. The method for treating severe heart failure according to claim 1, wherein the active compound is 5-hydroxy-7-chloro-1-[2-methyl-4-(2-methylbenzoylamino)-benzoyl]-2,3,4,5-tetrahydro-1H-benzazepine or a pharmaceutically acceptable salt thereof.

15 7. The method for treating severe heart failure according to any one of claim 1 to 6, wherein the severe heart failure is acute heart failure or a chronic heart failure in acute exacerbation.

20 8. The method for treating severe heart failure according to any one of claim 1 to 6, wherein the severe heart failure is a severe heart failure of New York Heart Association Class: III and IV.

25 9. A medicament for the treatment of severe heart failure which comprises as an active ingredient a benzazepine compound of the formula (1):




wherein R<sup>1</sup> is a hydrogen atom or a halogen atom, R<sup>2</sup> is a hydroxy group, or a group of the formula: -NR<sup>5</sup>R<sup>6</sup> wherein R<sup>5</sup> and R<sup>6</sup> are the same or different and are each a hydrogen atom or a lower alkyl group, R<sup>3</sup> is a hydrogen atom, a halogen atom, a lower alkyl group, or a lower alkoxy group, R<sup>4</sup> is a halogen atom, a lower alkyl group or a lower alkoxy group, or a pharmaceutically acceptable salt thereof.

10. The medicament according to claim 9, wherein the active compound (1) is 5-dimethylamino-1-[4-(2-methylbenzoylamino)benzoyl]-2,3,4,5-tetrahydro-1H-benzazepine or a pharmaceutically acceptable salt thereof.

11. The medicament according to claim 9, wherein the active compound (1) is 5-hydroxy-7-chloro-1-[2-methyl-4-(2-methylbenzoylamino)benzoyl]-2,3,4,5-tetrahydro-1H-benzazepine or a pharmaceutically acceptable salt thereof.

12. A pharmaceutical composition suitable for the treatment of severe heart failure, which comprises as an

active ingredient a benzazepine compound of the formula (1):



wherein R<sup>1</sup> is a hydrogen atom or a halogen atom, R<sup>2</sup> is a hydroxy group, or a group of the formula: -NR<sup>5</sup>R<sup>6</sup> wherein R<sup>5</sup> and R<sup>6</sup> are the same or different and are each a hydrogen atom or a lower alkyl group, R<sup>3</sup> is a hydrogen atom, a halogen atom, a lower alkyl group, or a lower alkoxy group, R<sup>4</sup> is a halogen atom, a lower alkyl group or a lower alkoxy group, or a pharmaceutically acceptable salt thereof in admixture with a conventional pharmaceutically acceptable carrier or diluent.


13. The pharmaceutical composition according to claim 12, wherein the active compound (1) is 5-dimethylamino-1-[4-(2-methylbenzoylamino)benzoyl]-2,3,4,5-tetrahydro-1H-benzazepine or a pharmaceutically acceptable salt thereof.

14. The pharmaceutical composition according to claim 12, wherein the active compound (1) is 5-hydroxy-7-chloro-1-[2-methyl-4-(2-methylbenzoylamino)benzoyl]-2,3,4,5-

tetrahydro-1H-benzazepine or a pharmaceutically acceptable salt thereof.

15. The pharmaceutical composition according to any one of claims 12 to 14, wherein the active compound (1) or 5 a pharmaceutically acceptable salt thereof is contained in an amount of 1 to 70 % by weight based on the weight of the composition.

16. A use of a benzazepine compound of the formula (1):



10

wherein R<sup>1</sup> is a hydrogen atom or a halogen atom, R<sup>2</sup> is a hydroxy group, or a group of the formula: -NR<sup>5</sup>R<sup>6</sup> wherein R<sup>5</sup> and R<sup>6</sup> are the same or different and are each a hydrogen atom or a lower alkyl group, R<sup>3</sup> is a hydrogen atom, a 15 halogen atom, a lower alkyl group, or a lower alkoxy group, R<sup>4</sup> is a halogen atom, a lower alkyl group or a lower alkoxy group, or a pharmaceutically acceptable salt thereof for manufacturing a medicament suitable for the treatment of severe heart failure.

17. The use of a benzazepine compound (1) or a pharmaceutically acceptable salt thereof according to claim 16, wherein the active compound (1) is 5-dimethylamino-1-[4-(2-methylbenzoylamino)benzoyl]-2,3,4,5-tetrahydro-1H-benzazepine or a pharmaceutically acceptable salt thereof.

18. The use of a benzazepine compound (1) or a pharmaceutically acceptable salt thereof according to claim 16, wherein the active compound (1) is 5-hydroxy-7-chloro-1-[2-methyl-4-(2-methylbenzoylamino)benzoyl]-2,3,4,5-tetrahydro-1H-benzazepine or a pharmaceutically acceptable salt thereof.

19. The use of a benzazepine compound (1) or a pharmaceutically acceptable salt thereof according to any one of claims 16 to 18, wherein the active compound (1) or a pharmaceutically acceptable salt thereof is contained in the medicament in a daily dosage unit of the range of less than 0.6 mg/kg.